Red Glead Discovery   Red Glead Discovery is a drug discovery company focused on development of therapies based on small molecules and peptides. Based on strong in-house laboratory capabilities, drug dsicvery expertise and solid industrial working knowledge of project leadership and IP protection, we perform a dual business model:   Offering of high-quality, cross-functional preclinical drug discovery services (CRO) Internal discovery programs focussed on generating high-quality lead compounds or clinical candidates often in collaboration with academic groups.   Both the services and projects are offered to pharmaceutical and biotechnology companies and organisations, preferably in a collaborative fashion. An expert area is generation of chemical starting points for drug targets and to develop them into patentable lead compounds with drug-like properties and low risk profile. These activities are supported by a versatile platform for fragment-based lead discovery that we share and continuously develop together with SARomics Biostructures. Our project management skills and cross-disciplinary capabilities make us a preferred partner for clients and partners that want to develop compounds with desired properties and high potential to become successful drugs.     RGD is a private company with 18 full time employees formed 2011 by ex-colleagues from AstraZeneca R&D Lund (70% PhDs, and >150 years of industrial pharma experience). Our laboratory capabilities comprise medicinal chemistry, custom design & synthesis of peptides and organic molecules, assay development and screening, radioisotope-labelling, analytical chemistry (HPLC, NMR and LC-MS/MS), bioanalysis and in vitro ADME. The mission of RGD is to facilitate more drugs and interventions reaching the market in order to improve people's health and quality of life.